Navigation Links
Cybrexa Therapeutics Appoints Vishwas Paralkar, Ph.D. as Chief Scientific Officer
Date:9/20/2017

Cybrexa Therapeutics, a start-up cancer therapeutics company, announced today that it has appointed Vishwas Paralkar to the role of chief scientific officer. In this role, Dr. Paralkar will lead the development of Cybrexa’s tumor targeting technology. He will report to Cybrexa’s president and CEO, Per Hellsund.

“I was impressed with Cybrexa’s revolutionary technology and excellent leadership team,” Dr. Paralkar said. “The team has had multiple past successes and I am excited to bring this technology to market.”

Dr. Paralkar has more than 20 years of experience in drug development, and brings extensive drug discovery expertise and knowledge to the team. He joins Cybrexa from Karos, Inc., where he was recently the chief scientific officer. Prior to that, he held numerous senior level positions at Pfizer. Vishwas is a very experienced drug developer responsible for submitting 8 INDs (including both small and large molecules) and one drug approval.

Hellsund commented, “We are very pleased to have Vishwas join our team. We are confident that his leadership and breadth of drug development experience will enable us to move our technology from the research stage into the clinic.”

Cybrexa is a privately funded biotechnology company dedicated to developing an entirely new class of small molecule DNA repair inhibitors and DNA damaging agents (TSDs) that directly target the tumor microenvironment. This approach will both improve the efficacy while at the same time reduce toxicity of existing cancer drugs. The Company has made significant progress since it’s inception and now has several drug candidates that are being run through its in vitro and in vivo screening platform. The objective is to have at least one of it’s TSDs ready for a phase I clinical trial within two years.

About Cybrexa:

Cybrexa was founded by successful entrepreneurs Hellsund, Kevin Didden and Kevin Rakin, who most recently built and successfully exited Cyvek, Inc. Hellsund serves as the President and CEO, and Didden and Rakin serve as board members. Additional members of the founding team include Ranjit Bindra, M.D., Ph.D., and Peter Glazer, M.D., Ph.D., from the Yale School of Medicine. Bindra and Glazer are both physician-scientists and world-renowned experts in DNA repair. Their work has been published in numerous high-impact journals, including Science, Nature, and Science Translational Medicine.

For more information about Cybrexa, please call 860-717-2731 or visit us on the web at http://www.cybrexa.com

Read the full story at http://www.prweb.com/releases/2017/09/prweb14715217.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Cybrexa Therapeutics Secures $6 Million in Series B Financing
2. Renova Therapeutics co-founder awarded highest research honor by the U.S. Department of Veterans Affairs
3. Lotus Clinical Research Executive to Present on Opioid Sparing Endpoints at 11th Annual Pain & Migraine Therapeutics Summit
4. Former VP of Clinical Pharmacology at Nektar Therapeutics, Michael A. Eldon, PhD, FCP, Joins NDA Partners as Expert Consultant
5. United Therapeutics Corporation Reports Second Quarter 2017 Financial Results
6. Myonexus Therapeutics, Inc. Launches to Develop Pioneering, Clinical-Stage Gene Therapies Targeting Limb-Girdle Muscular Dystrophies
7. Industry leaders join Renova Therapeutics to lead preclinical programs into clinical development
8. United Therapeutics Announces $250 Million Share Repurchase Program
9. Arrowhead Publishers’ 11th Annual Pain and Migraine Therapeutics Summit Set to Take Place This Fall in San Diego, CA
10. Open Therapeutics and the Center for Advancing Innovation Form Partnership
11. Brainstorm Cell Therapeutics to Present at ARMs 5th Annual Cell & Gene Therapy Investor Day, April 27 in Boston
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2018)... (PRWEB) , ... August 29, 2018 , ... ... Professorships at both the University of Southampton and the Institute of Industrial Science, ... intelligence at sea can dramatically accelerate the exploration and study of hard to ...
(Date:8/29/2018)... ... August 28, 2018 , ... Inc. Magazine has announced ... ranked in 1138th place on the 27th annual Inc. 5000, the most prestigious ... the most successful companies within the American economy’s most dynamic segment – independent ...
(Date:8/26/2018)... YORBA LINDA, Calif. (PRWEB) , ... August 23, ... ... interactive virtual events for tech innovators, engineers, and scientists from around the world, ... and Immunology 2018 will cover an array of industries and disciplines, encompassing various ...
(Date:8/21/2018)... ... August 21, 2018 , ... ... specializing in medical device compliance and commercialization, has just released a new ... Written and presented by Dr. Mario Kossmann, ESEP at the 28th Annual ...
Breaking Biology Technology:
(Date:9/24/2018)... ... September 24, 2018 , ... ... applications, is pleased to announce that starting on October 1, 2018 Hamamatsu will ... October 2017. , “We have been working steadfastly since our acquisition to integrate ...
(Date:9/22/2018)... ... 2018 , ... We are excited to announce the release ... recently launched NovoCyte QuanteonTM flow cytometers and NovoSampler® Q autosampler ... , In addition to the functionalities supporting the expanded flow cytometer products ...
(Date:9/22/2018)... ... September 21, 2018 , ... ... if left untreated, can lead to significant morbidity and mortality. VTE affects between ... diagnosed upon autopsy. Further, PE is the leading cause of preventable hospital death ...
Breaking Biology News(10 mins):